Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018801 (heart failure)
 72,216 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Palivizumab is now authorized in France for prophylaxis of respiratory syncytial virus (RSV) infections in infants with haemodynamically significant congenital cardiac disease. A multicentre randomised trial was shown that treatment was safe and effective for such children. The therapeutic protocol is similar to that used in preterm infants and consists of five, monthly, intramuscular injections of palivizumab, at a dose of 15 mg/kg, started 2 months before the onset of epidemic season. To guide clinicians to identify children most likely to benefit from prophylaxis, the Pediatric Cardiac Group of French Cardiac Society has proposed recommendations. Prophylaxis with palivizumab is recommended in high-risk infants for respiratory complications after RSV infection: infants under I year old; left to right shunt with cardiac failure, failure to thrive, pulmonary hypertension or bronchial compression; cyanotic heart disease with oxygen saturation lower than 0.8 at rest; congenital cardiac disease expected to need admission for surgery or catheterization during the epidemic season; cardiomyopathy with cardiac failure; primary or secondary pulmonary hypertension; symptomatic children aged over I year with complex cardiac disease. Decisions regarding prophylaxis with palivizumab should be made in collaboration with the pediatric cardiologist in order to optimize the cost-benefice ratio, on the basis of the degree of physiologic cardiovascular compromise.
 ...
PMID:[Use of palivizumab for the prevention of respiratory syncytial virus infections in children with congenital heart disease. Recommendations from the French Paediatric Cardiac Society]. 1551 44

Palivizumab (Synagis) is a monoclonal antibody directed against the respiratory syncytial virus (RSV), for reducing mortality and morbidity in infants at risk of cardio-respiratory impairement due to bronchiolitis: 1. prematurity less than 28 weeks and less than 1 year of age; 2. between 28 and 32 weeks plus mechanical ventilation and less than 6 months of age; 3. chronic lung deficiency and less than 2 years of age; 4. congenital cardiopathy with either desaturation, pulmonary hypertension or cardiac failure. Another group of infants is those having a severe imnnunodeficiency. These infants are listed in a hospital recognized to have a competence in neonatal intensive care or a cardio-thoracic care program. The specialist in those disciplines prescribe the palivizumab which is delivered by the pharmacy of the competent hospital. The infant receives it by IM route at a dose of 15 mg/kg, monthly between October or November and February or March. Reduction of mortality and morbidity have been observed in the infants at risk. However, this costly pharmacological preventive approach needs to come after other simple preventive measures such as avoiding contact with potential carriers of nasal viruses and passive smoking, for bronchiolitis is not solely due to RSV.
 ...
PMID:[Practical pediatric aspects of palivizumab]. 1964 67